3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide
C29H32N4O4 — CID 58486082
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide
3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide (PubChem CID 58486082) has the molecular formula C29H32N4O4 and a molecular weight of 500.60 g/mol. Its IUPAC name is 3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide.
Molecular Properties
| Compound Name | 3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide |
|---|---|
| PubChem CID | 58486082 |
| Molecular Formula | C29H32N4O4 |
| Molecular Weight | 500.60 g/mol |
| Exact Mass | 500.24 |
| IUPAC Name | 3-[[3-[5-(1-methylpiperidin-4-yl)oxy-2-pyridinyl]phenyl]methyl]-2-oxo-N-propyl-1,3-benzoxazole-5-carboxamide |
| SMILES | CCCNC(=O)c1ccc2oc(=O)n(Cc3cccc(-c4ccc(OC5CCN(C)CC5)cn4)c3)c2c1 |
| InChI | InChI=1S/C29H32N4O4/c1-3-13-30-28(34)22-7-10-27-26(17-22)33(29(35)37-27)19-20-5-4-6-21(16-20)25-9-8-24(18-31-25)36-23-11-14-32(2)15-12-23/h4-10,16-18,23H,3,11-15,19H2,1-2H3,(H,30,34) |
| InChIKey | RWIGDJKHGAAYRC-UHFFFAOYSA-N |
| XLogP | 4.32 |
| TPSA | 89.60 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 500.60 |
| LogP ≤ 5 | 4.32 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 58486082 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.